The science

The methodology and infrastructure behind banking healthy immune cells.

For physicians, researchers, and anyone who wants the fuller clinical picture—not just the story.

Cell isolation & analysis

What we isolate, and why it matters

From a standard blood draw, we isolate peripheral blood mononuclear cells (PBMCs)—including T cells (CD4 and CD8 subsets, further broken down into naive, central memory, and effector populations), B cells, monocytes, and NK cells. Each population is analyzed by flow cytometry for viability and relative levels, compared against demographic reference ranges, and compiled into a personalized report.

This analysis and report are not diagnostic. They characterize the health and viability of the cells collected—they do not detect, screen for, predict, or diagnose any disease or medical condition. Any medical concerns should be directed to your physician.

The goal is to bank cells at their healthiest, before illness, age, or treatment can compromise their quality or quantity—preserving a higher-quality starting sample for potential future use in cell-based therapies, including CAR-T cell therapy.

Processing methodology

[Method name / approach]

[Describe your actual isolation/cryopreservation protocol here—e.g. density gradient separation, controlled-rate freezing, cryoprotectant used. This is the section physicians and pharma partners scrutinize most, so accuracy matters more than polish.]

  • [Processing timeline, e.g. "processed within X hours of collection"]
  • [Viability thresholds / QC standards]
  • [Storage temperature and monitoring protocol]
Infrastructure

Built for the long term

Our laboratory in Buffalo, NY works with lab partners that follow CLIA and CAP standards. Samples are cryopreserved and stored at accredited biological sample storage facilities, for a term the client chooses—up to 10 years or indefinitely.

We're a young, deliberately careful company—every sample is handled individually, not processed at scale. If you'd rather know exactly how many people we've worked with or how long we've been doing this, just ask us directly.

Research context

Where this fits in cell therapy today

CAR-T and related cell therapies typically use a patient's own T-cells, collected at the time of treatment via leukapheresis. Banking healthy cells in advance is intended to preserve a higher-quality starting sample—collected before illness or prior treatment could reduce cell health or yield—for potential future use if such therapies become relevant.

[If you have specific research partnerships, published data, or a scientific advisory board, this is the place to name them with specifics rather than general claims.]

Stay informed

Want to know more about the science and reporting we do?

Leave your email and we'll send you a closer look at our methodology and personalized reporting—plus updates as our research evolves. No sales content, unsubscribe any time.

Physician, researcher, or partner organization? Visit our page for physicians & partners →